Slide Sets from the DRIVE-AB Final Conference: Revitalizing the Antibiotic Pipeline
Slide sets from presentations given at the DRIVE-AB Final Conference, held on 5-6 September 2017, in Brussels.
Quality indicators and quantitative metrics for responsible antibiotic use, lessons from DRIVE-AB project
Delivered by Vera Vlahovic-Palcevski, DRIVE-AB
British Society for Antimicrobial Chemotherapy Spring Conference, 14 March 2017, London.
DRIVE-AB – Driving Re-Investment in R&D and Responsible Antibiotic Use
Delivered by Stephan Harbarth, University of Geneva
COMBACTE-NET, COMBACTE-CARE and COMBACTE-MAGNET General Assembly, 14-16 March 2017, Brussels, Belgium
Ecology and environmental drivers of antibiotic resistance
Delivered by Ursula Theuretzbacher, Center for Anti-Infective Agents
International Meeting on Emerging Diseases and Surveillance, held on 4-7 November 2016, Vienna, Austria.
DRIVE-AB – Driving re-investment in R&D and responsible antibiotic use
Delivered by Work Package 2 Co-lead Christine Årdal, Norwegian Institute of Public Health
Organisation for Economic Co-operation and Development (OECD) Expert Group on the Economics of Prevention meeting, 11 October, 2016
Slide sets from the DRIVE-AB Conference: Stimulating innovation, sustainable use and global access to antibiotics
Slide sets from presentations given at the DRIVE-AB Conference, held on 2 June, 2016, in Amsterdam.
DRIVE-AB Train-the-Trainer Event: Defining and implementing responsible Antibiotic use, Part I
Delivered by Inge Gyssens, Jeroen Schouten and Marlies Hulscher
DRIVE-AB Train-the-Trainer event, Amsterdam, 2016
DRIVE-AB Train-the-Trainer Event: Defining and implementing responsible antibiotic use, Part II
Delivered by Céline Pulcini. Benedikt Huttner and Vera Vlahovic-Palcevski
DRIVE-AB Train-the-Trainer event, Amsterdam, 2016
Quality indicators of antibiotic use in the inpatient setting: a global consensus procedure
Delivered by DRIVE-AB Work Package 1A participant Annelie Monnier, Radboud University Medical Center at the European Congress on Clinical Microbiology and Infection, Amsterdam, 2016
Why should we care about multi-resistant bacteria? Clinical impact and public health implications
Delivered by Prof Stephan Harbarth, Université de Genève / Infection Control Program
Geneva Pharma Forum, Geneva, 2015
Enabling drug discovery and development to address the crisis of antibacterial resistance: New tools, new pathways and remaining challenges
Delivered by Dr John Rex, AstraZeneca
Geneva Pharma Forum, Geneva, 2015